Literature DB >> 23679279

Seroreactivity to Helicobacter pylori antigens as a risk indicator of gastric cancer.

Najmeh Karami1, Yeganeh Talebkhan, Samaneh Saberi, Maryam Esmaeili, Akbar Oghalaie, Afshin Abdirad, Ehsan Mostafavi, Mahmoud Eshagh Hosseini, Mohammad Ali Mohagheghi, Marjan Mohammadi.   

Abstract

BACKGROUND: Multiple etiologic factors are suspected to cause gastric cancer, the most important of which is infection with virulent types of Helicobacter pylori.
MATERIALS AND METHODS: We have compared 102 gastric cancer patients with 122 non-ulcer, non-cancer dyspeptic patients. Gastric specimens were evaluated for H. pylori infection by tissue-based detection methods. Patient sera underwent antigen-specific ELISA and western blotting using a Helicoblot 2.1 kit and antibody responses to various H. pylori antigens were assessed.
RESULTS: The absolute majority (97-100%) of both groups were H. pylori seropositive. Multivariate regression analysis demonstrated serum antibodies to the low molecular weight 35kDa protein to be protective and reduce the risk of gastric cancer by 60% (OR:0.4; 95%CI:0.1-0.9). Conversely, seroreactivity to the 89kDa (VacA) protein was significantly higher in gastric cancer patients (OR:2.7; 95%CI:1.0-7.1). There was a highly significant association (p<0.001) between seroreactivity to the 116kDa (CagA) and 89kDa (VacA) proteins, and double positive subjects were found at nearly five fold (OR:4.9; 95%CI:1.0-24.4) enhanced risk of gastric cancer as compared to double negative subjects.
CONCLUSIONS: Seroreactivity to H. pylori low (35kDa) and high (116kDa/89kDa) molecular weight antigens were respectively revealed as protective and risk indicators for gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23679279     DOI: 10.7314/apjcp.2013.14.3.1813

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

1.  Antibodies as biomarkers for cancer risk: a systematic review.

Authors:  Maria J Monroy-Iglesias; Silvia Crescioli; Kerri Beckmann; Nga Le; Sophia N Karagiannis; Mieke Van Hemelrijck; Aida Santaolalla
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

Review 2.  Helicobacter pylori infection: host immune response, implications on gene expression and microRNAs.

Authors:  Aline Cristina Targa Cadamuro; Ana Flávia Teixeira Rossi; Nathália Maciel Maniezzo; Ana Elizabete Silva
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

Review 3.  Diagnosis of Helicobacter pylori infection: Current options and developments.

Authors:  Yao-Kuang Wang; Fu-Chen Kuo; Chung-Jung Liu; Meng-Chieh Wu; Hsiang-Yao Shih; Sophie S W Wang; Jeng-Yih Wu; Chao-Hung Kuo; Yao-Kang Huang; Deng-Chyang Wu
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

4.  Effectiveness of 7-Day and 14-Day Moxifloxacin-Dexlansoprazole Based Triple Therapy and Probiotic Supplement for Helicobacter Pylori Eradication in Thai Patients with Non-Ulcer Dyspepsia: A Double-Blind Randomized Placebo-Controlled Study

Authors:  Peranart Chotivitayatarakorn; Varocha Mahachai; Ratha-Korn Vilaichone
Journal:  Asian Pac J Cancer Prev       Date:  2017-10-26

5.  Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study).

Authors:  Ratha-Korn Vilaichone; Natsuda Aumpan; Thawee Ratanachu-Ek; Pornpen Gamnarai; Tomahisa Uchida; Lotay Tshering; Varocha Mahachai; Yoshio Yamaoka
Journal:  Asian Pac J Cancer Prev       Date:  2020-04-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.